title: Evaluation of Ion Mobility-Mass Spectrometry for Comparative Analysis of Monoclonal Antibodies.
abstract: Analytical techniques capable of detecting changes in structure are necessary to monitor the quality of monoclonal antibody drug products. Ion mobility mass spectrometry offers an advanced mode of characterization of protein higher order structure. In this work, we evaluated the reproducibility of ion mobility mass spectrometry measurements and mobiligrams, as well as the suitability of this approach to differentiate between and/or characterize different monoclonal antibody drug products. Four mobiligram-derived metrics were identified to be reproducible across a multi-day window of analysis. These metrics were further applied to comparative studies of monoclonal antibody drug products representing different IgG subclasses, manufacturers, and lots. These comparisons resulted in some differences, based on the four metrics derived from ion mobility mass spectrometry mobiligrams. The use of collision-induced unfolding resulted in more observed differences. Use of summed charge state datasets and the analysis of metrics beyond drift time allowed for a more comprehensive comparative study between different monoclonal antibody drug products. Ion mobility mass spectrometry enabled detection of differences between monoclonal antibodies with the same target protein but different production techniques, as well as products with different targets. These differences were not always detectable by traditional collision cross section studies. Ion mobility mass spectrometry, and the added separation capability of collision-induced unfolding, was highly reproducible and remains a promising technique for advanced analytical characterization of protein therapeutics. Graphical Abstract ᅟ.
authors.affiliation: U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis, 645 S. Newstead Ave., St. Louis, MO, 63110, USA.|Pfizer Inc., Chesterfield, MO, USA.
authors.forename: Carly N
authors.initials: CN
authors.lastname: Ferguson
authors.affiliation: U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Division of Pharmaceutical Analysis, 645 S. Newstead Ave., St. Louis, MO, 63110, USA. ashley.gucinski@fda.hhs.gov.
authors.forename: Ashley C
authors.initials: AC
authors.lastname: Gucinski-Ruth
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D051379:Mice
chemical_list: D000911:Antibodies, Monoclonal
keywords: Higher order structure; Ion mobility-mass spectrometry; Monoclonal antibodies